Preliminary evaluation of novel 18F-AlF-NOTA-IF7 as a tumor imaging agent

  • Xiaobo Gu
  • Mengjun Jiang
  • Donghui Pan
  • Gangming Cai
  • Rongjun Zhang
  • Yaoyuan Zhou
  • Yaming Ding
  • Bao Zhu
  • Xiufeng Lin


Annexin 1 (Anxa1) is a highly specific surface marker of tumor vasculature. A carbohydrate ligand-mimicking 7-mer peptide, IFLLWQR (Ile-Phe-Leu–Leu-Trp-Gln-Arg, IF7) can target Anxa1 in tumor vasculature. IF7 was first conjugated with a macrocyclic chelator, 1, 4, 7- triazacyclononane-1, 4, 7- triacetic acid (NOTA), and the resulting bioconjugate NOTA-IF7 was then radiofluorinated via Al18F intermediate to synthesize 18F-AlF-NOTA-IF7. MicroPET studies demonstrated that 18F-AlF-NOTA-IF7 had good uptake in tumor. 18F-AlF-NOTA-IF7 is a promising radiopharmaceutical in tumor imaging. The favorable characterizations of 18F-AlF-NOTA-IF7 such as convenient synthesis, specific Anxa1 targeting and moderate tumor uptake make it possible for imaging of cancers.


Annexin 1 NOTA 18F-AlF-NOTA-IF7 MicroPET imaging 



This project was supported by the Science Foundation of Health Department of Jiangsu Province (H201226), the Fund of Wuxi Science and Technology Development (CSE31N1409), the Foundation of Wuxi Hospital Management Center (YGZXM14014), National Natural Science Foundation of China (81471736), the Vocational Education Science Foundation of Health Department of Jiangsu Province (JZ201413) and the Health Technology Planning Project of Jiangsu Province (Grant No. Q201204).


  1. 1.
    Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429:629–635CrossRefGoogle Scholar
  2. 2.
    Hatakeyama S, Sugihara K, Nakayama J, Akama TO, Wong SM, Kawashima H, Zhang J, Smith DF, Ohyama C, Fukuda M, Fukuda MN (2009) Identification of MRNA splicing factors as the endothelial receptor for carbohydrate-dependent lung colonization of cancer cells. Proc Natl Acad Sci USA 106:3095–3100CrossRefGoogle Scholar
  3. 3.
    Shingo H, Kazuhiro S, Toshiaki KS, Jun N, Tomoya OA, Naoaki T, Shuk-Man W, Andrey AB, Yutaka T, Chikara O, Minoru F, Michiko NF (2011) Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc Natl Acad Sci USA 108:19587–19592CrossRefGoogle Scholar
  4. 4.
    Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC (2010) A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med 51:454–461CrossRefGoogle Scholar
  5. 5.
    McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM (2009) A novel method of 18F radiolabeling for PET. J Nucl Med 50:991–998CrossRefGoogle Scholar
  6. 6.
    Laverman P, D’Souza CA, Eek A, McBride WJ, Sharkey RM, Oyen WJ, Goldenberg DM, Boerman OC (2012) Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol 33:427–434CrossRefGoogle Scholar
  7. 7.
    Vaidyanathan G, Zalutsky MR (1992) Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. Int J Radiat Appl Instrum B 19:275–281CrossRefGoogle Scholar
  8. 8.
    Lang L, Eckelman WC (1994) One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot 45:1155–1163CrossRefGoogle Scholar
  9. 9.
    Guhlke S, Coenan H, Stocklin G (1994) Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids. Appl Radiat Isot 45:715–727CrossRefGoogle Scholar
  10. 10.
    Wuest F, Kohler L, Berndt M, Pietzsch J (2009) Systematic comparison of two novel, thiol-reactive prosthetic groups for 18F labeling of peptides and proteins with the acylation agent succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). Amino Acids 36:283–295CrossRefGoogle Scholar
  11. 11.
    Marik J, Hausner SH, Fix LA, Gagnon MK, Sutcliffe JL (2006) Solid-phase synthesis of 2-[18F]fluoropropionyl peptides. Bioconjug Chem 17:1017–1021CrossRefGoogle Scholar
  12. 12.
    Guhlke S, Wester HJ, Bruns C, Stocklin G (1994) (2-[18F]fluoropropionyl-(D)phel)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 21:819–825CrossRefGoogle Scholar
  13. 13.
    Li ZB, Wu Z, Chin FT, Chen X (2007) Click chemistry for 18F-labeling of RGD peptides and microPET imaging of tumor integrin αvβ3 expression. Bioconjug Chem 18:1987–1994CrossRefGoogle Scholar
  14. 14.
    Kiesewetter DO, Guo N, Guo J, Gao H, Zhu L, Ma Y, Niu G, Chen X (2012) Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics 2:999–1009CrossRefGoogle Scholar
  15. 15.
    Dijkgraaf I, Franssen GM, McBride WJ, D’Souza CA, Laverman P, Smith CJ, Goldenberg DM, Oyen WJ, Boerman OC (2012) PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 53:947–952CrossRefGoogle Scholar
  16. 16.
    Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z (2011) One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Mol Imaging 38:1732–1741CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2015

Authors and Affiliations

  • Xiaobo Gu
    • 1
  • Mengjun Jiang
    • 2
  • Donghui Pan
    • 1
  • Gangming Cai
    • 1
  • Rongjun Zhang
    • 1
  • Yaoyuan Zhou
    • 1
  • Yaming Ding
    • 3
  • Bao Zhu
    • 4
  • Xiufeng Lin
    • 5
  1. 1.Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear MedicineJiangsu Institute of Nuclear MedicineWuxiChina
  2. 2.Department of Clinical Laboratory ScienceNanjing Medical University, Affiliated Wuxi Peoples HospitalWuxiChina
  3. 3.Wuxi Higher Health Vocational Technology SchoolWuxiChina
  4. 4.Department of Nuclear MedicineNanjing Medical University, Affiliated Wuxi Peoples HospitalWuxiChina
  5. 5.Department of PathologyJiangsu Institute of Nuclear MedicineWuxiChina

Personalised recommendations